University of Sydney is launching a robust study in an attempt to, as the university describes, “investigate cannabis consumption, behaviours, and attitudes among users.”

Part of the study involves offering free, anonymous cannabis testing for people that cultivate their own cannabis in the Australian Capital Territory (ACT).

Free cannabis testing is available to both medical patients and non-medical patients, although only people that are current residents of the ACT can participate.

A member of the Australian Greens says fresh legal advice paves a clear path for the national legalisation of cannabis.

Aussie basketball legend Lauren Jackson was a pain-riddled 'zombie' before medicinal cannabis allowed her to make a remarkable comeback aged 41​​

The acquisition was announced in March this year, and APIRx stakeholders received almost 218.17 million new Incannex shares at a notional value of $0.573 each. The new shares are subject to a 12-month escrow for the vendors.

As part of the deal, APIRx founders Dr George Anastassov and Lekhram Changoer have joined Incannex as non-executive director and chief technical officer, respectively.

When a pink glow lit up the evening sky above an Australian town on Wednesday, local woman Tammy Szumowski wondered if the apocalypse had arrived.

Wellnex Life’s (ASX: WNX) strategy to penetrate the medicinal cannabis and hemp market in Australia is a step closer under a joint venture with Victoria-based producer OneLife Botanicals.

OneLife is a licensed cannabis producer and manufacturer and has what Wellnex describes as a world-class cannabis production, research and development facility.

It is licensed to generate up to 20 tonnes of product a year.

Under the joint venture terms, Wellnex will have the “first right of refusal” on OneLife’s cannabis-based raw materials and products, which will be sold under a jointly developed brand.

An "ethically approved" clinical trial to test whether cannabis can replace opioids in the management of chronic pain has kicked off in SA, with "very promising" results in the pilot phase.

This is according to a statement from investment holding company Labat Africa, which has a focus on medical cannabis. Labat, which is listed on both the JSE and Frankfurt stock exchanges, exports over a quarter of its SA health Products Regulatory Authority-approved medical cannabis crop from Kenton-on-Sea to Australia and Europe.

Its recent acquisitions include Miami-owned CBD brand Echo Life.

It’s been more than five years since Australia first introduced a medicinal cannabis program, and a new study has shed light on who exactly gets those scripts.

As reported by The Guardian, researchers from University of Sydney revealed a bunch of juicy statistics around who is being given prescriptions, and for what conditions. It found that chronic pain was the most common reason for medical cannabis being recommended to patients, accounting for 61 percent of prescriptions. Anxiety made up 16 percent of scripts, and sleep disorders 5.6 percent.

The study also shows that pre-pandemic, the age group receiving prescriptions ranged from 45 to 52-years-old. But since 2020, prescriptions are predominantly going to a much younger group, aged 20 to 31.

It is hoped a Shepparton research project will unearth answers on the effects of cannabis oils in cannabis users.

The 12-week project is seeking anonymous participants to determine the efficacy of Cannabidiol oil for mood and sleep issues in cannabis users.

The study, led by Shepparton-based Professor Edward Ogden, will include 33 participants who will meet with a researcher monthly to record results.

CBD oil is an alternative therapy which has promising results in trials for treating addiction around the world.

CBD, unlike Tetrahydrocannabinol — the other main compound found in marijuana — contains no psychoactive or addictive qualities.